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Background: Elective treatment of lymph nodes in oropharyngeal cancer (OPC) has impact on both regional recurrences
(RR) and risk of late side effects. This study was performed to quantify the dose-dependent impact on RR and overall
survival (OS) in a prospectively collected cohort of OPC from the ARTSCAN study with emphasis on elective treatment.
Methods: ARTSCAN is a previously published prospective, randomized, multicentre study of altered radiotherapy
(RT) fractionation in head and neck cancer. In ARTSCAN the elective treatment volume for node positive OPC varied
significantly between centres due to local treatment principles. All patients with OPC in complete response after
primary treatment were eligible for the present case–control study. Cases were patients with RR during five years
follow-up. Patients with no recurrence were eligible as controls. Four controls per case were matched according to
T- and N-stage. Mean (Dmean) and median (D50%) dose for the lymph node level (LNL) of RR in the cases and the
corresponding LNL in the controls were analysed with conditional logistic regression. OS was estimated with the
Kaplan-Meier method and evaluated by multivariate Cox regression analysis.
Results: There was a dose-dependent risk reduction for D50% in the interval that represented elective treatment
(40–50 Gy) (OR = 0.18, p < 0.05) and a trend in the same dose interval for Dmean (OR = 0.19, p = 0.07). OS rates at
five years were 0.39 (0.24-0.65) for cases and 0.70 (0.62–0.81) for controls (p < 0.001). The Kaplan-Meier and the
Cox regression analysis for cases categorised by delivered dose showed an inverse relationship between dose and survival.
The cases with RR in a LNL outside planning target volume (PTV) (Dmean < 40 Gy) had an OS rate comparable to
that of all patients, and those with RR in a LNL in PTVelective (Dmean 40–60 Gy) or PTVtumour (Dmean >60 Gy) did
significantly worse (p < 0.05). The same inverse relationship was also shown for a small subset of patient with known
HPV-status, defined by over expression of p16 (p < 0.05).
Conclusions: There was a significant risk reduction for RR of elective treatment. However the OS for patients with RR
outside target volumes was not affected, with similar results for patients with HPV-positive OPC. This could be an
argument for a prospective randomized study on limited elective target volumes in OPC.Background
Elective radiotherapy (RT) of clinically negative regional
lymph nodes has been part of the standard treatment in
head and neck squamous cell carcinoma (HNSCC) for
many decades [1, 2]. Several retrospective studies have
shown the efficacy of this treatment, but few studies have
addressed the dose–response relationships based on the ac-
tual dose distribution to the lymph nodes rather than* Correspondence: karin.soderstrom@onkologi.umu.se
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creativecommons.org/publicdomain/zero/1.0/prescribed dose [3–7]. On the other hand, knowledge about
relationships between side effects and doses to organs at
risk (OARs) is expanding. A number of models that esti-
mate the probability of normal tissue complications link
different dose-volume descriptors for OARs with the inci-
dence of specific side effects, for example dysphagia [8–10].
Since the introduction of three dimensional conformal
radiotherapy (3D-CRT) and later intensity modulated
radiotherapy (IMRT) and volumetric arc therapy with
highly conformal dose distributions, it is possible to bet-
ter spare OARs to reduce side effects [11–14]. One spe-
cific sub-group of HNSCC, oropharyngeal cancer (OPC),ess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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The disease occurs at a younger age and is more often
associated with human papilloma virus (HPV) than with
tobacco and alcohol abuse [15–19].
As the treatment options evolve and the disease itself
changes a reassessment of the current treatment seems
motivated.
ARTSCAN was a prospective randomised controlled
multi-centre study on accelerated versus conventional
fractionation [20]. No significant differences between the
fractionation schedules concerning tumour control or
late side effects were detected. A large proportion of the
patients (48 %) had OPC. At the time of the study there
was no clear national consensus on elective treatment.
In the study protocol, the elective target volume was
specified as “the standard recommendation at each treat-
ing institution” with a dose prescription of 46 Gy in 23
fractions, 5 days per week, in both treatment arms. Some
centres practiced limited elective treatment with unilateral
and selective (not treating all LNL of the neck) treatment
and some used bilateral treatment including all LNL of
the neck in node positive disease. There was a significant
difference, up to a factor of two, between different study
sites regarding the volumes prescribed for elective treat-
ment in node positive OPC [21]. Due to this variation in
elective treatment volume, not solely dependent on
tumour stage, it is reasonable to use this prospectively col-
lected material to estimate a dose–response relationship
for regional recurrences corrected for T- and N -stage.
Therefore we studied the dose-dependent risk reduc-
tion of neck node recurrences as well as survival based
on regional recurrences in patients treated with defini-
tive RT in this prospectively collected cohort of OPC.
Methods
Objectives and study design
The objectives of the study were:
1. To compare mean and median dose of a lymph
node level (LNL) with a regional recurrence to mean
and median dose of the corresponding LNL in
matched controls without recurrence. This was
carried out as a case–control study.
2. To analyse the impact of regional recurrence on
overall survival (OS). This was done both for cases
vs. controls and for cases grouped according to
mean dose separately.
Patients
The cohort from which the cases and controls were re-
cruited consisted of all OPC patients with complete re-
sponse to primary treatment in an earlier reported
prospective randomised controlled trial, ARTSCAN [20].
Complete response, in this study, was defined as noresidual tumour after primary treatment and no local or
regional failure within 6 months after randomisation.
The ARTSCAN study was approved by the participating
centres’ local Ethics Committees (Regional ethics commit-
tee Umeå) and 733 eligible patients with localised HNSCC
signed informed consent between 1998 and 2006. About
half of them (n = 357) had OPC. Neither chemotherapy nor
surgery, other than diagnostic, prior to RT was allowed.
Neck dissection as part of primary treatment post RT was
allowed according to clinical practice at each participating
centre. The use of neck dissection post RT varied between
centres where some practiced planned elective neck dis-
section and some centres used salvage neck dissection in
patients with suspected/verified residual neck disease. For
additional information on the original study, see [20]. Two
of the sites (Stockholm and Umeå) have since the publica-
tion of [20] provided information on HPV-status (based on
p16-expression as a surrogate marker) for patients with
OPC. An extensive quality assurance process for the ori-
ginal study was performed and published [21] with no
major trends in the patient characteristics or treatment of
OPC during the study period.
Cases for the present study were patients with a regional
relapse with or without composite local relapse during
follow up. They were identified by the clinical report form
and verified in the patient chart. The remaining patients in
the cohort with loco-regional control during the follow-up
period of five years were eligible as controls. Frequency
matching was performed based on T- and N-stage, and to
optimise the statistical power of the study, four controls
were chosen for each case.Radiotherapy
All patients received computed tomography (CT) based
3D-CRT (92 %) or IMRT (8 %) with dose prescriptions ac-
cording to ICRU [22, 23]. The RT and the quality assurance
of the trial have been described in detail elsewhere [20, 21].
Patients included in the ARTSCAN trial were randomised
between two fractionation schedules for the planning target
volume encompassing macroscopic tumour (PTVtumour).
The conventional fractionation schedule (CFx) consisted of
2 Gy fractions daily/5 days a week to a total dose of 68 Gy
with a total treatment time <7 weeks. Patients receiving ac-
celerated fractionation (AFx) were prescribed 2 Gy frac-
tions daily/5 days a week plus a daily concomitant boost
of 1.1 Gy to a total dose of 68 Gy with a total treatment
time <5 weeks for PTVtumour. As stated in the introduc-
tion, all patients had a dose prescription of 46 Gy in
2 Gy fractions daily/5 days a week to the elective PTV
(PTVelective), the extent of which was not stipulated in
the protocol. The major difference between centres in
respect to PTVelective was the use of unilateral selective
treatment in T1-2 and N1-2b OPC.
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The patients were clinically examined 4–8 weeks after
completion of RT to assess treatment result. During the
first two years patients were monitored for loco-regional
relapse and distant metastases every 3 months, and they
were monitored every 6 months thereafter until five
years after end of RT. OS was followed through the
Swedish population registry.
Treatment plans (CT-images, structures, plans and
dose distribution) from ARTSCAN were collected after
RT was completed and stored in DICOM-RT format for
additional analysis such as the present.
All cases had their charts revised including available
radiological imaging to identify the LNL [24, 25] of
the regional relapse including side in respect to the
primary tumour (ipsilateral vs. contralateral). The cor-
responding LNL for the controls including laterality
was identified. A systematic delineation of the LNL ac-
cording to [26, 27] was performed by one of the au-
thors (KS) on the original CT-images for all cases and
controls. Dose-volume data for these structures were
derived from the original DICOM-RT dose files using
the software package RT Bench™ (Cureos AB, Uppsala,
Sweden).
Dose-volume analysis
We analysed mean dose (Dmean) and median dose (D50%)
for the LNL of relapse in the cases and the correspond-
ing LNL in the controls.
The derived doses for both cases and controls were
grouped according to delivered dose to the LNL of interest
for the calculation of any dose–response relationships.
Four dose intervals were chosen representing LNLs: out-
side PTV (0–40 Gy), within PTVelective (40–50 Gy), in
PTVelective close to PTVtumour (50–60 Gy), and PTVtumour
(>60 Gy), respectively.
Immunohistochemistry of p16
Tumour biopsy sections (4–5 μm) were de-paraffinised
and rehydrated, with antigen retrieval in citrate buffer
(pH 6) and unspecific binding sites blocked with 1.5 %
horse serum in PBS. The sections were then stained with
mAb p16INKA4a (clone: JC8, dilution 1:100, Santa Cruz
Biotech, Santa Cruz, CA, USA) at +8 °C overnight, before
incubation for 45 min. with biotinylated anti-mouse anti-
body (dilution 1:200, Vector Laboratories, Burlingame,
CA, USA). Alternatively, the slides were stained with the
CINtec® p16 Histology (805–4713), Ventana Medical Sys-
tems Inc., Arizona, USA by following the same protocol
with the exception of incubation with the antibody for 1 h
at room temperature. For antigen detection, the avidin–
biotin–peroxidase complex (ABC) kit (Vectastain, Vector
Laboratories, Burlingame, CA, USA) was used. Slides de-
veloped in chromogen 3’-diaminobenzydine (DAB) (VectorLaboratories, Burlingame, CA, USA) and counterstained
with haematoxylin were then washed and dehydrated, and
the cover mounted using VectaMount permanent mount-
ing media (Vector Laboratories, Burlingame, CA, USA).
P16 staining was regarded as positive if >70 % of the
tumour cells were strongly p16-positive [28, 29].Statistical analysis
For univariate analyses the Pearson Chi-Squared-test
and Fisher’s exact test were used. The odds ratios for
Dmean and D50% grouped according to dose intervals
were calculated using conditional logistic regression.
Clinically suspected interactions with the dose–response
data were also evaluated in the model.
The Kaplan-Meier method was used to estimate OS
for all patients calculated from start of RT to death or
censoring. Univariate survival time comparisons between
cases and controls as well as between cases divided by
mean dose to LNL of interest were performed using the
log-rank test. Kaplan-Meier survival curves were com-
plemented with a multivariate Cox regression, adjusting
for potential confounders. All two-way interaction terms
were evaluated in the model.
All tests were two-sided and p-value of less than 0.05
was considered statistically significant.
Data were analysed with the statistical software pack-
age R (version 2.15.2; R Development Core Team, R
foundation for Statistical Computing, Vienna, Austria).Results
Eligibility and patient characteristics
In the cohort of OPC patients with complete response
from ARTSCAN, 23 cases with a recurrence in the
lymph nodes of the neck were identified corresponding
to a regional relapse rate of 7.2 %. Five (22 %) of these
regional recurrences had a composite local recurrence.
A majority of the cases (95.6 %) and the controls
(96.6 %) were in clinical stage III-IV (UICC, Geneva,
1987). 46.6 % of the controls and 43.5 % of the cases were
treated with the AFx-schedule. Median age (58 years for
cases and 59 years for controls) and other tumour and
patient characteristics, including predictive factors re-
ported in [20], showed no significant difference be-
tween cases and controls (Table 1). About half of the
patients had a neck dissection as part of their primary
treatment post RT, and for those the pathology speci-
men was reviewed for viable tumour (Table 2). In the
subset (n = 42) with reported HPV-status (based on p16
expression) there was no significant difference between
cases and controls (Table 1). In conclusion, none of the
tested two-way interactions differed between cases and
controls.
Table 1 Patient and tumour characteristics
Controls Case Total
n (%) n (%) n (%) p value
T 1 19 (21.6) 5 (21.7) 24 (21.6) 1.000
2 28 (31.8) 7 (30.4) 35 (31.5)
3 24 (27.3) 6 (26.1) 30 (27.0)
4 17 (19.3) 5 (21.7) 22 (19.8)
Total 89 (100) 23 (100) 111 (100)
N 0 10 (11.4) 3 (13.0) 13 (11.7) 0.069
1 23 (26.1) 2 (8.7) 25 (22.5)
2A 25 (28.4) 4 (17.4) 29 (26.1)
2B 15 (17.0) 10 (43.5) 25 (22.5)
2C/3 15 (17.0) 4 (17.4) 19 (17.1)
Total 89 (100) 23 (100) 111 (100)
Sex male 66 (75.0) 19 (82.0) 85 (76.6) 0.584
female 22 (25.0) 4 (17.4) 26. (23.4)
Total 88 (100) 23 (100) 111 (100)
Hb conc <140 37 (49.3) 14 (66.7) 51 (53.1) 0.217
>140 38 (50.7) 7 (33.3) 45 (46.9)
Total 75 (100) 21 (100) 96 (100)
PS Karnofsky <90 6 (7.2) 3 (13) 9 (8.5) 0.465
>90 77 (92,8) 20 (87) 97 (91.5)
Total 83 (100) 23 (100) 106 (100)
HPV-status (>70 % p16+) + 28 (82.4) 6 (75.0) 34 (81.0) 0.635
- 6 (17.6) 2 (25.0) 8 (19.0)
Total 34 (100) 8 (100) 42 (100)
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The dose–response relationships, presented as odds ra-
tios, between cases and controls for the analysed dose
intervals including the number of cases and controls an-
alyzed in each interval are presented in Table 3. There
was a significant risk reduction for a RR in D50% for the
interval representing elective treatment (40–50 Gy) and
a trend for Dmean in the same dose interval. We have
evaluated the model by adjusting for treatment type and
neck dissection without any alterations in the signifi-
cance levels presented in Table 3.Table 2 Neck dissection (ND) as part of primary treatment after defi
Control
n (%)
ND Yes 54 (61.4)
No 34 (38.6)
Total 88 (100)
If ND, viable tumour present Yes 15 (27.8)
No 39 (72.2)
Total 54 (100)Survival
OS rates (95 % CI) at five and twelve years for the co-
hort were 0.72 (0.68–0.77) and 0.57 (0.5–0.65). A RR re-
sulted in significantly reduced OS (Fig. 1). The OS rates
at five and twelve years were 0.39 (0.24–0.65) and 0.29
(0.15–0.56) for the cases and 0.7 (0.62–0.81) and 0.6
(0.49–0.74) for the controls respectively. The Kaplan-
Meier analysis for all cases categorised by mean dose to
LNL with RR (Fig. 2) showed an inverse relationship be-
tween dose and survival. The OS rates were significantly
higher for cases with a relapse in a LNL outside PTVnitive RT
Case Total p value
n (%) n (%)
11 (47.8) 65 (58.6) 0.342
12 (52.2) 46 (41.4)
23 (100) 111 (100)
3 (27.3) 18 (28.1) 0.219
7 (63.6) 46 (71.2)
10 (100) 64 (100)
Table 3 Dose–response relationship




















>60 9/31 0.65 0.650
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4/6
Relationship between dose to lymph node level (LNL) of interest and regional
recurrences presented as odds ratio (OR). Dose interval presented in Gy, the
distribution of cases/controls per dose interval is presented below the
dose interval
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lapse in a LNL in the elective volume (Dmean 40–60 Gy)
(0.40 (0.14–1.00) and in PTVtumour (Dmean >60 Gy) (0.11
(0.02–0.71). A similar relative inverse relationship was
shown for the more limited number of cases with known
HPV-status (by p16 over expression in >70 % of the cells)
divided in two groups according to Dmean. OS rate at five
years was 0.5 (0.25–1.00) for Dmean <60 Gy and none were
alive at 5 years for Dmean >60 Gy (p = 0.046).
Complementing the results presented in Fig. 1, we per-
formed a Cox regression with OS as dependent variable,
adjusting for fractionation schedule (AFx vs. CFx) and
neck surgery. The variables representing time to relapse
and neck surgery were analyzed as a time-dependent
(i.e. time at risk is counted from the day of the event
until either end of follow up or death). The results are
presented in Table 4. No tested two-way interactions
were statistically significant. When comparing cases and
controls and not taking date of recurrence into account
(i.e. not analyzing recurrence as a time-dependent vari-
able) the hazard ratio for cases vs. controls was 2.74(95 % CI 1.44–5.21). A Cox regression analysis was also
performed for cases only, with outcome OS comple-
menting Fig. 2, comparing dose categories (≤40 Gy, 40 ≤
60 Gy, >60 Gy) adjusted for fractionation schedule and
neck surgery (analyzed as a time-dependent variable),
Table 5. No tested two-way interactions were statistically
significant.Discussion
Our material indicates a risk reduction for regional re-
currences (OR < 0.2) in the dose interval corresponding
to elective treatment (40–50 Gy) with statistical signifi-
cance in the logistic regression model for D50% and a
trend for Dmean. No significant risk reduction for re-
gional relapse was found in our study for Dmean and
D50% in the other investigated dose intervals. One ex-
planation for the lack of risk reduction for development
of RR in D50% and Dmean >50 Gy could be the close
proximity to macroscopic tumour in these LNLs and
thereby an inherent higher risk of relapse where a dose
<60 Gy might not be sufficient. However, the number of
cases and controls in this dose interval is small. A simi-
lar dose as suggested in our material has been proposed
for elective treatment to the neck in recent studies
where an equivalent dose in 2 Gy fractions, assuming α/
β = 10 Gy (EQD210) > 50 Gy, does not seem to improve
regional control [30, 31], whereas a dose < 30 Gy in 2 Gy
fractions has been shown to have a higher regional re-
lapse rate [32]. A prospective randomised trial investi-
gating an EQD210 of 40 Gy to PTVelective presented
encouraging toxicity outcome regarding dysphagia, but
not yet tumour control data [33].
As the cohort for the present study consisted of pa-
tients with complete response after primary treatment,
the OS of the cohort was somewhat better than the sur-
vival of all OPS presented in [20]. In our study a re-
gional relapse resulted in significantly reduced OS,
both at five and twelve years. However, when deciding
which LNLs to include in an elective target volume, the
consequence on OS of a nodal recurrence outside of
the target volume is highly relevant. The effect on OS
of regional relapses categorised by delivered dose, how-
ever, is sparsely addressed in the literature. This
prompted us to do a survival analysis for the cases
grouped according to Dmean representing a relapse out-
side of the PTV (<40 Gy), in the PTVelective (40–
60 Gy), or in the PTVtumour (>60 Gy). A recurrence in
PTVtumour has a major impact on OS, whereas a patient
with a nodal relapse outside the PTVs has a survival
comparable to that of the cohort. Our hypothesis, to
this perhaps somewhat contra intuitive finding, is that
the relapses in such heavily treated areas are selected to





















Number of patients at risk: 
Cases: 
Controls: 
23 21 18 15 11 9 9 8 6 4 3 2 2
88 84 79 75 71 64 61 47 34 27 17 8 5
Log-rank test, p-value = 0.0009
Fig. 1 Overall survival in cases and controls. Kaplan-Meier plot of overall survival in cases and controls (95 % CI)
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treatment options.
The finding that recurrences “out of field” have a sur-
vival comparable to the cohort could be an argument for
future studies investigating limited elective target vol-
umes omitting treatment to LNL with low risk of relapse
in order to avoid late side effects of the treatment.
Since HPV is one of the most important prognostic fac-
tors in OPC treated with RT [34–37], we evaluated the OS
in the cases with HPV-positive tumours divided according
to Dmean to examine if the inverse relationship between
dose and survival seen in all cases holds true for the HPV-
positive cases as well. Because of the small number of
cases with known HPV-status we restricted the analysis to
Dmean ≤60 Gy or Dmean >60 Gy in this group. In spite of
the small number of cases there was still a significant dif-
ference in OS in patients with HPV-positive OPC divided
according to dose similar to that shown for all cases. Re-
cently a review of risk factors for loco-regional failure in
HPV-associated OPC found that the only factors signifi-
cant for risk stratification in multivariate analysis apart
from smoking were T4- and N3-stages [38], which were
evenly distributed in our study between cases and con-
trols. Only five of the HPV-positive cases had available
smoking status (all non-smokers). Three of those had
Dmean ≤60 Gy and two had Dmean >60.Two different fractionation schedules were used for
the PTVtumour in the present study. The ARTSCAN
study showed no significant difference in treatment re-
sponse of lymph node metastases or regional relapses
between the fractionation schedules and the use of AFx in
our study. Thus the study was well balanced between cases
and controls. Therefore no significant difference in out-
come depending on fractionation schedule was expected.
Today advanced head and neck cancer is commonly
treated with chemo-RT which has shown a survival
benefit compared to RT alone [39]. The presented dose–
response relationships in this study are investigated for
RT without chemotherapy. Since HPV-associated OPC
has a favourable outcome, voices are being raised for a
possible de-escalation of the treatment to this entity of
HNSCC [18, 37, 40]. The incidence of HPV-associated
OPC is steadily increasing and now constitutes up to 85 %
of all OPC in Sweden [16, 17]. Therefore we suggest that
dose–response relationships for RT without chemotherapy
are clinically relevant.
According to the ARTSCAN-study protocol, the PTV
elective was defined according to clinical practice at each
participating centre. At the time of the study there was
no clear consensus on what to treat electively in Sweden.
This resulted in an up to two- fold variation in the size of


























9 9 9 8 6 6 6 6 6 4 3 2 2
5 4 4 4 3 2 2 1 0 0 0 0 0
9 8 5 3 2 1 1 1 0 0 0 0 0
Log-rank test, p-value = 0.0215
Fig. 2 Overall survival in cases based on mean dose (Dmean). Kaplan-Meier plot of overall survival in cases divided according to mean dose to LNL
of interest
Söderström et al. Radiation Oncology  (2015) 10:117 Page 7 of 9selective elective treatment in the study. Therefore the
variation of dose delivered to the LNLs of the neck was
only partly dependent on T- and N-stage. This allows ana-
lysis of dose–response relationships of regional recur-
rences corrected for tumour stage. Moreover, the present
study was performed on a patient material consisting
solely of OPC, which reduces the possible bias of different
risk of metastatic spread with respect to primary tumour
site.
Conclusions
Our study shows a significant risk reduction for the de-
velopment of regional recurrences of elective treatmentTable 4 Overall survival in cases and controls
HR CI p-value
Regional relapse 3.56 1.84–6.92 <0.001
Fx-schedule 0.88 0.49–1.59 0.673
Neck dissection 0.85 0.45–1.60 0.619
Cox regression analysis of overall survival in cases vs. controls adjusted for
fractionation schedule and neck dissectionin the dose levels used in the present study compared
to no prescribed elective treatment in OPC. However,
in 319 patients treated with RT without chemother-
apy, only 23 nodal recurrences occurred during five
years of follow-up. Moreover the OS for patients with
regional recurrence outside target volumes was not
affected, with a similar pattern for a small subset of
patients with known HPV-status. This could be an
argument for a prospective randomised study on lim-
ited elective target volumes to reduce late side effects
in OPC.Table 5 Overall survival in cases based on mean dose (Dmean)
HR CI p-value
40–60 1.67 0.35–7.98 0.522
60–80 7.94 1.80–35.04 0.006
Fx-schedule 1.96 0.54–7.17 0.310
Neck dissection 1.83 0.59–5.67 0.298
Cox regression analysis of overall survival in cases categorised according to
dose interval in Gy adjusted for fractionation schedule and neck dissection.
Dose <40 Gy is the reference category
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